Skip to content

Shortystrap Effectiveness in the Treatment of the Pathology Pubic and Abdominal Pathology in Athletes

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02882399
Acronym
Shortystrap
Enrollment
49
Registered
2016-08-29
Start date
2013-04-12
Completion date
2015-11-06
Last updated
2019-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pubic and Abdominal Pathology

Keywords

athletes

Brief summary

The pubic and abdominal pathology is common among athletes. It leads to a shutdown of physical activity for several months, and requires rehabilitative care, or surgery for a permanent cure. Shortystrap is designed to avoid surgery and allow the continuation of sports.

Interventions

OTHERShortystrap

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Male * Sports practicing physical activity at least 3 hours per week * Practicing a team sport with a major part of running (football, rugby, ...) * Presenting a pubic and abdominal pathology for at least 4 weeks * In primary consultation * Age from 18 to 40 years * Informed consent signed

Exclusion criteria

* Professional athlete * Cyclist * Having already received usual medical treatment (anti-inflammatory treatment and rest) * Introducing another disease requiring treatment with NSAIDs * Allergy neoprene * Contraindications to performing MRI (claustrophobia, any metal device, pacemaker, etc.) * Simultaneous participation in another biomedical research * Major person under legal protection (backup justice, trusteeship, guardianship), person deprived of liberty.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of pain using a scale FerettiDay 15scale Feretti

Secondary

MeasureTime frameDescription
Evaluation of pain using a visual analog scaleDay 15, Day 30 and Day 60visual analog scale

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026